Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 11/20 | 0.42 |
| ▸ | REN | P00797 | 5/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899004 | 0.76 | MAPT (0.41) | REN | |
| SCHEMBL30860430 | 0.72 | ADORA2A (0.44) | RENKMO | |
| SCHEMBL14909654 | 0.72 | ADORA2A (0.44) | RENKMO | |
| SCHEMBL19597355 | 0.69 | GLS (0.66) | — | |
| SCHEMBL14908867 | 0.68 | CNR2 (0.46) | KMO | |
| SCHEMBL30860213 | 0.68 | CNR2 (0.46) | KMO | |
| SCHEMBL29855564 | 0.67 | CHRM2 (0.39) | RENKMOPDE7A | |
| SCHEMBL91359 | 0.67 | REN (0.46) | RENKMO | |
| SCHEMBL16898929 | 0.66 | MAPT (0.38) | REN | |
| SCHEMBL13132264 | 0.66 | REN (0.46) | RENKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082644-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | CURIS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-12178821-B2 | Combination therapies for the treatment of cancer | CURIS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20220370422-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-20220339161-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-10-27 | — | — | US | disclosed |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082644-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | IRAK4, IRAK2, IRAK3 | KHK 3053/4885REN 4849/4885NTRK1 2078/4885 |
| US-20220370422-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | KHK 1371/4885REN 4207/4885NTRK1 3731/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | KHK 1282/4885REN 4433/4885NTRK1 2644/4885 |
| US-12178821-B2 | Combination therapies for the treatment of cancer | IRAK4, IRAK2, IRAK3 | KHK 3053/4885REN 4849/4885NTRK1 2078/4885 |
| US-20220339161-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | KHK 1282/4885REN 4433/4885NTRK1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.